Platinum, palladium, gold and ruthenium complexes as anticancer agents: Current clinical uses, cytotoxicity studies and future perspectives

被引：333
作者：
Lazarevic, Tatjana [1 ]
Rilak, Ana [2 ]
Bugarcic, Zivadin D. [2 ]
机构：
[1] Univ Kragujevac, Fac Med, S Markovic 69, Kragujevac 34000, Serbia
[2] Univ Kragujevac, Fac Sci, R Domanovica 12,POB 60, Kragujevac 34000, Serbia
来源：
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2017年 / 142卷
关键词：
Anticancer agents; Cytotoxicity; DNA; Proteins; IN-VITRO CYTOTOXICITY; DNA-BINDING PROPERTIES; STRUCTURAL-CHARACTERIZATION; SUBSTITUTION-REACTIONS; POLYPYRIDYL COMPLEXES; ANTITUMOR-ACTIVITY; PT(II) COMPLEXES; THIOREDOXIN REDUCTASE; CELLULAR PHARMACOLOGY; SACCHARINATE COMPLEX;
D O I：
10.1016/j.ejmech.2017.04.007
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Metallodrugs offer potential for unique mechanism of drug action based on the choice of the metal, its oxidation state, the types and number of coordinated ligands and the coordination geometry. This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have different modes of action and on prodrug and targeting strategies in an effort to diminish the side-effects of cisplatin chemotherapy. Examples of metal compounds and chelating agents currently in clinical use, clinical trials or preclinical development are highlighted. (C) 2017 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：8 / 31
页数：24
相关论文
共 146 条
  • [1] Platinum group antitumor chemistry: Design and development of new anticancer drugs complementary to cisplatin
    Abu-Surrah, AS
    Kettunen, M
    [J]. CURRENT MEDICINAL CHEMISTRY, 2006, 13 (11) : 1337 - 1357
  • [2] In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer
    Aird, RE
    Cummings, J
    Ritchie, AA
    Muir, M
    Morris, RE
    Chen, H
    Sadler, PJ
    Jodrell, DI
    [J]. BRITISH JOURNAL OF CANCER, 2002, 86 (10) : 1652 - 1657
  • [3] Synthesis, characterization and theoretical calculations of (1,2-diaminocyclohexane)(1,3-diaminopropane)gold(III) chloride complexes: in vitro cytotoxic evaluations against human cancer cell lines
    Al-Jaroudi, Said S.
    Altaf, Muhammad
    Al-Saadi, Abdulaziz A.
    Kawde, Abdel-Nasser
    Altuwaijri, Saleh
    Ahmad, Saeed
    Isab, Anvarhusein A.
    [J]. BIOMETALS, 2015, 28 (05) : 827 - 844
  • [4] Alessio E., 2011, Bioinorganic Medicinal Chemistry
  • [5] Allardyce CS, 2001, PLATIN MET REV, V45, P62
  • [6] Synthesis and characterisation of some water soluble ruthenium(II)-arene complexes and an investigation of their antibiotic and antiviral properties
    Allardyce, CS
    Dyson, PJ
    Ellis, DJ
    Salter, PA
    Scopelliti, R
    [J]. JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2003, 668 (1-2) : 35 - 42
  • [7] Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer
    Andre, T
    Boni, C
    Mounedji-Boudiaf, L
    Navarro, M
    Tabernero, J
    Hickish, T
    Topham, C
    Zaninelli, M
    Clingan, P
    Bridgewater, J
    Tabah-Fisch, I
    de Gramont, A
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) : 2343 - 2351
  • [8] Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy
    Ang, Wee Han
    Dyson, Paul J.
    [J]. EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) : 4003 - 4018
  • [9] [Anonymous], 2003, Drugs R D, V4, P369
  • [10] Ruthenium-based chemotherapeutics: are they ready for prime time?
    Antonarakis, Emmanuel S.
    Emadi, Ashkan
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (01) : 1 - 9
12345678910